Addition of montelukast versus double dose of inhaled budesonide in moderate persistent asthma

Respirology

Volumn 9, Issue 2, 2004, Pages 243-248

  Yildirim, Zeki ^a   Ozlu, Tevfik ^b   Bulbul, Yilmaz ^b   Bayram, Hasan ^c  

^a SSK Hospital   (Turkey)

^b KARADENIZ TECHNICAL UNIVERSITY   (Turkey)

^c DICLE UNIVERSITY   (Turkey)

Author keywords

Asthma treatment; Budesonide; Leukotriene receptor antagonist; Moderate asthma; Montelukast

Indexed keywords

BUDESONIDE; CORTICOSTEROID; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST;

ADULT; ARTICLE; ASTHMA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; MALE; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SPIROMETRY;

ACETATES; ADULT; ASTHMA; BRONCHODILATOR AGENTS; BUDESONIDE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LEUKOTRIENE ANTAGONISTS; MALE; QUINOLINES; SPIROMETRY;

EID: 3142672720     PISSN: 13237799     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2004.00555.x     Document Type: Article

References (23)

1. Global Initiative for Asthma, Workshop Report. Global Strategy for Asthma Management and Prevention. National Institutes of Health, Bethesda, 2002.
2. Chang CC, Tam AY. Suppression of adrenal function in children on inhaled steroids. J. Paediatr. Child Health 1991; 27: 232-4.
3. Derom E, Van Schoor J, Verhaeghe W, Vincken W, Pauwels R. Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma. Am. J. Respir. Crit. Care Med. 1999; 160: 157-61.
4. Brown PH, Blundell G, Greening AP, Crompton GK. Hypothalamo-pituitary- adrenal axis suppression in asthmatics inhaling high dose corticosteroids. Respir. Med. 1991; 85: 501-10.
5. Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy. A systematic review and meta-analysis. Arch. Intern. Med. 1999; 159: 941-55.
6. Sivri A, Coplu L. Effect of the long-term use of inhaled corticosteroids on bone mineral density in asthmatic women. Respirology 2001; 6: 131-4.
7. Rand CS, Nides M, Cowles MK, Wise RA, Connett J. Long-term metered-dose inhaler adherence in a clinical trial. The Lung Health Study Research Group. Am. J. Respir. Crit. Care Med. 1995; 152: 580-8.
8. Simmons MS, Nides MA, Rand CS, Wise RA, Tashkin DP. Trends in compliance with bronchodilator inhaler use between follow-up visits in a clinical trial. Chest 1996; 109: 963-8.
9. Shrewsbury S, Pyke S, Britton M. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). BMJ 2000; 320: 1368-73.
10. Pauwels RA, Löfdahl CG, Postma DS et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N. Engl. J. Med. 1997; 337: 1405-11.
11. Kalra S, Swystun VA, Bhagat R, Cockcroft DW. Inhaled corticosteroids do not prevent the development of tolerance to the bronchoprotective effect of salmeterol. Chest 1996; 109: 953-6.
12. Bhagat R, Kalra S, Swystun VA, Cockcroft DW. Rapid onset of tolerance to the bronchoprotective effect of salmeterol. Chest 1995; 108: 1235-9.
13. Lofdahl CG, Svedmyr N. Beta-agonists-friends or foes? Eur. Respir. J. 1991; 4: 1161-5.
14. Lipworth BJ. Leukotriene-receptor antagonists. Lancet 1999; 353: 57-62.
15. Nayak AS, Anderson P, Charouss BL, Williams K, Simonson S. Equivalence of adding zafirlukast and double-dose inhaled corticosteroids in asthmatic patients symptomatic on low-dose inhaled corticosteroids. J. Allergy Clin. Immunol. 1998; 101: S233.
16. Laviolette M, Malmstrom K, Lu S et al. Montelukast added to inhaled beclomethasone in treatment of asthma. Montelukast/Beclomethasone Additivity Group. Am. J. Respir. Crit. Care Med. 1999; 160: 1862-8.
17. Tamaoki J, Kondo M, Sakai N et al. Leukotriene antagonist prevents exacerbation of asthma during reduction of high-dose inhaled corticosteroid. The Tokyo Joshi-Idai Asthma Research Group. Am. J. Respir. Crit. Care Med. 1997; 155: 1235-40.
18. Löfdahl CG, Reiss TF, Leff JA et al. Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients. BMJ 1999; 319: 87-90.
19. Price DB, Hernandez D, Magyar P et al. Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma. Thorax 2003; 58: 211-16.
20. Busse W, Nelson H, Wolfe J, Kalberg C, Yancey SW, Rickard KA. Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma. J. Allergy Clin. Immunol. 1999; 103: 1075-80.
21. Vaquerizo MJ, Casan P, Castillo J et al. Effect of montelukast added to inhaled budesonide on control of mild to moderate asthma. Thorax 2003; 58: 204-10.
22. Reiss TF, Chervinsky P, Dockhorn RJ, Shingo S, Seidenberg B, Edwards TB. Montelukast, a once-daily leukatriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double blind trial. Montelukast Clinical Research Study Group. Arch. Intern. Med. 1998; 158: 1213-20.
23. Minoguchi K, Kohno Y, Minoguchi H et al. Reduction of eosinophilic inflammation in the airways of patients with asthma using montelukast. Chest 2002; 121: 732-8.